Literature DB >> 9048293

Life-threatening retroperitoneal hematoma caused by anticoagulant therapy for myocardial infarction after SWL.

R Katz1, D Admon, D Pode.   

Abstract

Extracorporeal shock wave lithotripsy, the primary treatment for renal and ureteral stones, is an elective procedure with a low rate of complications, although most patients have macrohematuria which lasts for a few hours, and as many as 25% develop a renal or perirenal hematoma. Therefore, SWL is not performed during anticoagulant therapy, and any blood dyscrasias should be corrected prior to the procedure. We present a case of a patient who had an acute myocardial infarction after SWL, was treated with anticoagulation and emergency coronary angioplasty, and subsequently developed a life-threatening retroperitoneal hemorrhage. Cessation of anticoagulation with fluid support and drainage of a pleural effusion eventually resulted in complete recovery.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9048293     DOI: 10.1089/end.1997.11.23

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  4 in total

1.  Shock wave lithotripsy in patients requiring anticoagulation or antiplatelet agents.

Authors:  Bader Alsaikhan; Sero Andonian
Journal:  Can Urol Assoc J       Date:  2011-02       Impact factor: 1.862

Review 2.  Stone management for the patient on anticoagulation.

Authors:  Julie M Riley; Timothy D Averch
Journal:  Curr Urol Rep       Date:  2012-06       Impact factor: 3.092

Review 3.  Thromboprophylaxis and bleeding diathesis in minimally invasive stone surgery.

Authors:  Andreas Bourdoumis; Theodora Stasinou; Stefanos Kachrilas; Athanasios G Papatsoris; Noor Buchholz; Junaid Masood
Journal:  Nat Rev Urol       Date:  2013-12-17       Impact factor: 14.432

Review 4.  How can and should we optimize extracorporeal shockwave lithotripsy?

Authors:  Christian G Chaussy; Hans-Göran Tiselius
Journal:  Urolithiasis       Date:  2017-11-25       Impact factor: 3.436

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.